Share
Simon Read
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, has appointed Simon Read, Ph.D., to its Board of Directors.
The company also announced that Lonnie Moulder will transition off the Board.
Dr. Read is a seasoned biopharmaceutical entrepreneur with more than 30 years of industry experience. He most recently served as CEO and founder of Mariana Oncology until its acquisition by Novartis and previously as Chief Scientific Officer at Ra Pharma prior to its acquisition by UCB Pharma. Earlier in his career, he held R&D leadership positions at GlaxoSmithKline, AstraZeneca, and Roche/Genentech, contributing to the clinical development of leading immunology therapies, including Rituxan® and Actemra®.
A Fellow of the Royal Society of Medicine (UK), Dr. Read currently serves as Chairman of the Board of Ethyreal Bio and has previously served on the Boards of Triana Biomedicines and Oxstem Ltd (UK). He earned his Ph.D. from the University of Hertfordshire, studied Physiology at the University of Manchester, and has authored more than 50 peer-reviewed publications.
